455-58-3

Basic information

• Product Name: 2-Bromo-6-fluoro-4-nitroaniline
• Synonyms: 2-Bromo-6-fluoro-4-nitroaniline;2-BroMo-6-fluoro-4-nitro-phenylaMine
• CAS NO: 455-58-3
• Molecular Formula: C₆H₄BrFN₂O₂
• Molecular Weight: 235.0105632
• Mol File: 455-58-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 333.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.896±0.06 g/cm3(Predicted)
• PKA: -2.70±0.20(Predicted)
• CAS DataBase Reference: 2-Bromo-6-fluoro-4-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-6-fluoro-4-nitroaniline(455-58-3)
• EPA Substance Registry System: 2-Bromo-6-fluoro-4-nitroaniline(455-58-3)

Safety Data

• Hazardous Substances Data: 455-58-3(Hazardous Substances Data)

Usage

Uses

2-Bromo-6-Fluoro-4-nitroaniline is used in preparation of Phenylenediamines via Imination of Fluoroanilines with DMF followed by Amination and elimination with Amines.

Upstream product

• 369-35-7 2-fluoro-4-nitroaniline 

Downstream Products

• 952664-94-7 2-tert-butyl-7-fluoro-5-nitro-1H-indole 
• 952664-93-6 N-[2-(3,3-dimethylbut-1-ynyl)-6-fluoro-4-nitrophenyl]-butyramide 
• 952664-95-8 2-tert-butyl-7-fluoro-1H-indol-5-amine 
• 952664-92-5 2-(3,3-dimethylbut-1-ynyl)-6-fluoro-4-nitrophenylamine 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.